|
 |
Awards
2011
1. Steven Kao International Studentship presented by Pfizer Oncology at the Sixth Annual Cancer Institute of NSW Premier’s Awards for Outstanding Cancer Research in 2011.
2. Nico van Zandwijk Recognition of ‘Outstanding contributions to cancer research in NSW’ at the Sixth Annual Cancer Institute of NSW Premier’s Awards for Outstanding Cancer Research in 2011.
2010
3. Steven Kao ‘Best of the Best’ Oral Award. Clinical Oncological Society of Australia. 2010 Annual Scientific Meeting, Cancer and Beyond.
Peer-reviewed Articles
2012
1. Linton A, Vardy J, Clarke S, van Zandwijk N. The ticking time-bomb of asbestos: Its insidious role in the development of malignant mesothelioma. Critical Reviews in Oncology/Hematology. 2012: 2012 Mar 26. [Epub ahead of print]
2. Kirschner MB, Cheng YY, Badrian B, Kao SC, Creaney J, Edelman JJB, Armstrong NJ, Vallely MP, Musk AW, Robinson BWS, McCaughan BC, Klebe S, Mutsaers SE, van Zandwijk N, Reid G. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. 2012: In press
3. Manegold C, van Zandwijk N, Szczesna A, Zatloukal P, Au JSK, Blasinska-Morawiec M, Serwatowski P, Krzakowski M, Jassem J, Tan HE, Benner RJ, Ingrosso A, Meech SJ, Readett D, Thatcher N. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Annals of Oncology 23: 72–77, 2012
4. Lasham A, Samuel W, Cao H, Patel R, Mehta R, Stern JL, Reid G, Woolley AG, Miller LD, Black MA, Shelling AN, Print CG, Braithwaite AW. YB-1, the E2F Pathway, and Regulation of Tumor Cell Growth J Natl Cancer Inst 2012;104:133–146
2011
5. Weder W, Stahel RA, Baas P, Dafni U, de Perrot M, McCaughan BC, Nakano T, Pass HI, Robinson BW, Rusch VW, Sugarbaker DJ, van Zandwijk N. The MARS feasibility trial: conclusions not supported by data. Lancet Oncol. 2011 Nov;12(12):1093-4; author reply 1094-5.
6. Kao SC, Klebe S, Henderson DW, Reid G, Chatfield M, Armstrong NJ, Yan TD, Vardy J, Clarke S, van Zandwijk N, McCaughan B. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol. 2011 Nov;6(11):1923-9
7. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: association with disease and potential use as Biomarkers. Critical Reviews in Oncology/Hematology 2011 80: 193–208.
8. Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van Zandwijk N, Reid G. Haemolysis during sample preparation alters microRNA content of plasma. PLoS ONE doi: 2011;6(9):e24145. Epub 2011 Sep 1
9. Kao SC, Griggs K, Lee K, Armstrong N, Clarke S, Vardy J, van Zandwijk N, Burn J, McCaughan BC, Henderson DW, Klebe S. Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma. Pathology. 2011 Jun; 43 (4):313-7.
10. Herbert M, Coppieters N , Lasham A, Cao H, Reid G. The importance of RT-qPCR primer design for the detection of siRNA-mediated mRNA silencing. BMC Research Notes 2011,4:148
11. Heigener DF, Wu YL, van Zandwijk N, Mali P, Horwood K, Reck M. Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study. Lung Cancer. 2011 Nov;74(2):274-9. Epub 2011 Mar 24
12. Kao SC, Lee K, Armstrong NJ, Clarke S, Vardy J, van Zandwijk N, et al. Validation of tissue microarray technology in malignant pleural mesothelioma. Pathology. 2011 Feb;43(2):128-32.
13. Kao SC-H, Reid G, van Zandwijk N Henderson DW, Klebe S. Molecular Biomarkers in Malignant Mesothelioma - State of the Art. Pathology 2011;43(3):201-12.
14. Kao SC-H, Yan T, Lee K, Burn J, Henderson DW, Klebe S, Kennedy C, Vardy J, Clarke S, van Zandwijk N, McCaughan BC. Accuracy of Diagnostic Biopsy for the Histological Subtype of Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 2011 Jan
24;6(3):602-5.
2010
15. Li Y, Revalde J, Reid G, Paxton J. Modulatory effects of curcumin on multi-drug resistance associated protein 5 in pancreatic cancer cells. Cancer Chemotherapy and Pharmacology. 2010 Nov 30. [Epub ahead of print]
16. Reck M, van Zandwijk N, Gridelli C, Baliko Z, Rischin D, Allan S, et al. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer. 2010;5(10):1616-22.
17. Li Y, Revalde JL, Reid G, Paxton JW. Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer. Drug Metab Rev. 2010 Nov;42(4):590-611.
18. Lasham A, Herbert M, Coppieters 't Wallant N, Patel R, Feng S, Eszes M, Cao H, Reid G. A rapid and sensitive method to detect siRNA-mediated mRNA cleavage in vivo using 5' RACE and a molecular beacon probe. Nucleic Acids Res. 2010; 38(3):e19.
19. Kappers I, van Sandick JW, Burgers SA, Belderbos JS, van Zandwijk N, Klomp HM. Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoided. Lung Cancer. 2010; 68(2):222-7.
20. Kao SC, Reid G, Lee K, Vardy J, Clarke S, van Zandwijk N. Malignant Mesothelioma. Internal Medicine Journal. [Review]. 2010; 40:742–50.
21. Kao SC, Phan VH, Clarke SJ. Predictive markers for haematological toxicity of pemetrexed. Curr Drug Targets. 2010 ;11(1):48-57.
22. Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N, Clarke S. High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy. Clin Cancer Res. 2010; 16(23):5805-13.
23. Kao SC, McCaughan B, Muljono A, Boyer M. A pathological complete response in malignant pleural mesothelioma after combination chemotherapy with Carboplatin and pemetrexed. J Thorac Oncol. 2010; 5(3):405-6.
24. Kao SC, Butow P, Bray V, Clarke SJ, Vardy J. Patient and oncologist estimates of survival in advanced cancer patients. Psycho-Oncology 2010: DOI: 10.1002/pon.1727
25. Cheng YY, Chau D, Chan T, Gill H, Liang R, Kwong YL, et al. Absence of NPM1 promoter hypermethylation in human myelodysplastic syndrome. J Clin Pathol. 2010; 63(11):1008-11.
2009
26. van Zandwijk N. Individualization of treatment in non-small cell lung cancer. F1000 Medicine Reports. 2009;1:pii:24.
27. Van den Heuvel MM, Burgers SA, van Zandwijk N. Immunotherapy in non-small-cell lung carcinoma: from inflammation to vaccination. Clin Lung Cancer. 2009 Mar;10(2):99-105.
28. Smit EF, Groen HJ, van Zandwijk N. Reply to L. de Lima Aroujo et al. . J Clin Oncol. 2009;28(2):e26.
29. Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJ. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2009 Apr 20;27(12):2038-45.
30. Roepman P, Jassem J, Smit EF, Muley T, Niklinski J, van de Velde T, Witteveen AT, Rzyman W, Floore A, Burgers S, Giaccone G, Meister M, Dienemann H, Skrzypski M, Kozlowski M, Mooi WJ, van Zandwijk N. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res. 2009 Jan 1;15(1):284-90.
31. Reid G, Wallant NC, Patel R, Antonic A, Saxon-Aliifaalogo F, Cao H, et al. Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase. J RNAi Gene Silencing. 2009;5(1):321-30.
32. Patel R, T'Wallant N C, Herbert MH, White D, Murison JG, Reid G. The potency of siRNA-mediated growth inhibition following silencing of essential genes is dependent on siRNA design and varies with target sequence. Oligonucleotides. 2009 Dec;19(4):317-28.
33. Kappers I, van Sandick JW, Burgers JA, Belderbos JS, Wouters MW, van Zandwijk N, et al. Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection. Eur J Cardiothorac Surg. 2009 Oct;36(4):741-6.
34. Kao S, Mahon K, Lin B, Rutland J, Pawsey C, McCaughan B, et al. Pleural Well-Differentiated Papillary Mesothelioma. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer. [A Case Report]. 2009;4:920-2.
35. Geurts TW, van Velthuysen ML, Broekman F, van Huysduynen TH, van den Brekel MW, van Zandwijk N, et al. Differential diagnosis of pulmonary carcinoma following head and neck cancer by genetic analysis. Clin Cancer Res. 2009 Feb 1;15(3):980-5.
36. Geurts TW, Balm AJ, van Velthuysen ML, van Tinteren H, Burgers JA, van Zandwijk N, et al. Survival after surgical resection of pulmonary metastases and second primary squamous cell lung carcinomas in head and neck cancer. Head Neck. 2009 Feb;31(2):220-6.
Book Chapters
2010
1. van Zandwijk N. Occurrence and chemoprevention of lung cancer. In: Manegold C, editor. Non-small cell lung cancer treatment. Beijing: People's Medical Publishing House; 2010. p. 117-33.
2. van Zandwijk N. Lung Carcinogenesis and Chemoprevention. In Manegold C. Non-Small Cell Lung cancer Treatment. 2md Ed. Uni-Med Verlag AG. Bremen 2010; 15:165-176
3. van Zandwijk N. Chemoprevention. In: Pass HI, eds., et.al. Principals and practice of Lung Cancer: the official reference text of the ISALC. 4th Ed. Lippincott, Williams & Wilkens, Philadelphia, USA. 2010
2009
4. van Zandwijk N. Lung cancer: oncogenesis and prevention. In: Thoracic Malignancies. Spiro SG, Huber RM, Janes SM, editors. The European Respiratory Monograph, Plymouth, UK: European Respiratory Society Journals; 2009: 1-14
Conference Presentations
2012
1. Kirschner MB, Cheng YY, Badrian B, CreaneyJ, Edelman JJB, Musk AW, Robinson BWS, Klebe S, van Zandwijk N, Reid G. Assessment of circulating miRNAs as potential biomarkers for Malignant Pleural Mesothelioma (MPM) 3rd European Lung Cancer Conference. Geneva, Switzerland 18-21 April 2012
2. Kirschner MB, Kao SC, Edelman JJB, Armstrong NJ, Vallely MP, van Zandwijk N, Reid G. Effect of haemolysis on levels of circulating microRNAs Quantitative Real-Time PCR for Molecular Diagnostics Conference. San Francisco 16-17 February 2012.
2011
3. Linton A, Klebe S, Kao S et al. Pathological Diagnosis of Malignant Pleural Mesothelioma: Utilisation of immunohistochemical markers across Australia. Medical Oncology Group of Australia ASM ,Adelaide August 2011
4. Linton A, Klebe S, Griggs K, et al. The Prognostic role of Polo-like kinase 1 (PLK1) and Cell Division Control 2 (CDC2) expression in malignant pleural mesothelioma. Clinical Oncology Society of Australia ASM, Perth November 2011.
5. Glen Reid. Molecular characterisation of malignant mesothelioma to identify new markers and therapeutic targets. Asian Professional Network for Asbestos Related Issues (APNARI) Meeting, Seoul, Republic of Korea. 25-27 November 2011
6. Nico van Zandwijk. Keynote Speech: Asbestos: A wolf in sheep’s clothing. Action urgently needed. The 4th Asian Asbestos Initiative International Seminar. Pusan National University Yangsan Hospital, Republic of Korea. 16-18 November 2011
7. Nico van Zandwijk. Translating Research into better outcomes for patients with Asbestos-related disease and their families. The 4th Asian Asbestos Initiative International Seminar. Pusan National University Yangsan Hospital, Republic of Korea. 16-18 November 2011
8. Nico van Zandwijk. Malignant pleural mesothelioma: update from recent meetings. Australia Medical Conference: Evolving strategies to improve survival in advanced non-small cell lung cancer (NSCLC) – Lilly Oncology Symposium. Melbourne. 16-18 September 2011
9. Nico van Zandwijk. Biomarkers. NCARD, Victoria Park Golf Complex, Brisbane. 24 August 2011
10. Glen Reid. miRNA as a biomarker for mesothelioma. NCARD, Victoria Park Golf Complex, Brisbane. 24 August 2011
11. Pieter E. Postmus, Nico van Zandwijk (Co-chair) 14th World Conference on Lung Cancer. Amsterdam. 3-7 July 2011.
12. Steven C-H Kao Calretinin expression improves the predictive accuracy in survival in patients with malignant pleural mesothelioma (MPM) undergoing extrapleural pneumonectomy (EPP). 14th World Conference on Lung Cancer. Amsterdam. 3-7 July 2011. Journal of Thoracic Oncology 2011; 6(6) Suppl: (MO07.02) S534
13. Michaela B Kirschner Y-Box-binding protein I: a potential subtype-specific therapeutic target in malignant mesothelioma. 14th World Conference on Lung Cancer. Amsterdam. 3-7 July 2011. Journal of Thoracic Oncology 2011; 6(6) Suppl: (MO11.04) S572-3
14. Glen Reid An RNAi screen identifies new molecular targets in malignant mesothelioma. 14th World Conference on Lung Cancer. Amsterdam. 3-7 July 2011. Journal of Thoracic Oncology 2011; 6(6) Suppl: (MO13.12) S595-6
15. Glen Reid Discussant (MO23.10) 14th World Conference on Lung Cancer. Amsterdam. 3-7 July 2011.
16. Nico van Zandwijk. The evolving role of biomarkers in NSCLC. Personalised medicine in NSCLC: Myth or reality. CMI Education Institute Satellite Symposium. 4 July 2011 RAI Conference Centre, Plenary Room, Amsterdam.
17. Keunchil Park, Nico van Zandwijk. (Chairs) Lung cancer in never-smokers. (PL02) Plenary session. 14th World Conference on Lung Cancer. Amsterdam. 5 July 2011
18. Frances Shepherd, Nico van Zandwijk. (Chairs) Based on long experience: What brings the future? (M27) 14th World Conference on Lung Cancer. Amsterdam. 7 July 2011
19. Vera Hirsh, Nico van Zandwijk. (Chairs) Biomarkers VIII. (MO22) 14th World Conference on Lung Cancer. Amsterdam. 7 July 2011
2010
20. Glen Reid A rapid and sensitive method to detect siRNA-mediated mRNA cleavage in vivo using 5' RACE and a molecular beacon probe, RNAi2010: gene regulation by small RNAs, Oxford, UK, March 2010.
21. Nico van Zandwijk Asbestos & Disease: From Epidemiology and Prevention to Diagnosis and Treatment. Union Aid Abroad – APHEDA, National Institute of Labour Protection in Vietnam in collaboration with the Australian Manufacturing Workers’ Union (AMWU) & the Asbestos Disease Research Institute (ADRI) Meeting. Hanoi 9-10 April 2010
22. Nico van Zandwijk Screening of Asbestos-exposed Individuals. 2nd European Lung Cancer Conference – IASLC (International Association for the Study of Lung Cancer) and ESMO (European Society for Medical Oncology). Geneva 28 April - 1 May 2010.
23. Steven C-H Kao, Pavlakis N, Abraham R, et al. Validation of blood neutrophil-to-lymphocyte ratio as a prognostic factor in patients with malignant mesothelioma undergoing chemotherapy. Sydney Cancer Conference (SCC). 14-16 July University of Sydney; 2010.
24. Michaela B Kirschner, Lyn Schedlich, Yuen Yee Cheng, Nico van Zandwijk, Glen Reid.Y-Box-binding protein 1: a potential therapeutic target in malignant mesothelioma. International Mesothelioma Interest Group Conference 2010 (IMIG) Kyoto, Japan 31 Aug -3 Sept 2010
25. Glen Reid Circulating microRNAs as Markers of Malignant Mesothelioma. International Mesothelioma Interest Group Conference 2010 (IMIG) Kyoto, Japan 31 Aug -3 Sept 2010
26. Steven Kao Nick Pavlakis, R Abraham, et al. Validation of blood neutrophil-to-lymphocyte ratio as a prognostic factor in patients with malignant mesothelioma. International Mesothelioma Interest Group Conference 2010 (IMIG) Kyoto, Japan 31 Aug -3 Sept 2010
a. (Awarded a Vojakovic Fellowship – Melbourne Community Foundation travel grant)
27. Nico van Zandwijk Chemoprevention of high risk patient populations. 2nd International Thoracic Oncology Congress Dresden 16- 18th September 2010
28. Nico van Zandwijk Screening of asbestos exposed individuals. 3rd Australian Lung Cancer Conference (ALCC) 2010 Melbourne 7-9 October 2010
29. Nico van Zandwijk Identification of high risk individuals for chemopreventative measures. 3rd Australian Lung Cancer Conference (ALCC) 2010 Melbourne 7-9 October 2010
30. Nico van Zandwijk IASLC – World Conference Update. 3rd Australian Lung Cancer Conference (ALCC) 2010 Melbourne 7-9 October 2010
31. Steven C-H Kao, Clarke S, Harvie R, et al. Relationship between markers of systemic inflammation and clinical symptoms and survival in patients with malignant mesothelioma (MM). European Society of Medical Oncology Conference Milan 8-12 October 2010.
32. Glen Reid Translational Research at the ADRI. NCARD Annual Scientific Meeting, Perth 20-21 October 2010
33. Nico van Zandwijk Translational studies in malignant mesothelioma. Seventh Perth Mesothelioma Group Symposium, Perth 26 November 2010.
34. Nico van Zandwijk Methods of earlier detection of mesothelioma. National Institute of Labour Protection (NILP) Conference. Hanoi, Vietnam 21 December 2010
Conference Posters
2012
1. Kirschner MB, Kao SC, Edelman JJB, Armstrong NJ, Velley MP, van Zandwijk N, Reid G. Effect of haemolysis on levels of circulating microRNAs. Quantitative Real-Time PCR for Molecular Diagnostics Conference – 16-17 Feb 2012 San Francisco
2011
2. Laws P, Huang L, Raftery A, Sim MR, Musk W, Anderson A, Hill J, Armstrong B, van Zandwijk N. Australian mesothelioma registry. Clinical Oncological Society Australia (COSA) Annual Scientific Meeting (ASM) 15 - 17 Nov 2011 Perth.
3. Yuen Yee Cheng, Michaela B Kirschner, Hongchuan Jin, Francis K.L. Chan, Nico van Zandwijk, Glen Reid. Funcitional significance of Z1C1 and HSA-MIR-23A over-expression in malignant mesothelioma. Journal of Thoracic Oncology 2011; 6(6) Suppl: (P1.086):S753
4. Yuen Yee Cheng, Chris McLaughlin, Hongchuan Jin, Francis K.L. Chan, Michaela B Kirschner, Tony George, Nico van Zandwijk, Glen Reid. Epigenetic inactivation of the SFRP family by DNA methylation in malignant mesothelioma. Journal of Thoracic Oncology 2011; 6(6) Suppl: (P1.087):S753-4
5. Lyn Schedlich, Sumedha Gattani, Nico van Zandwijk, Glen Reid. The inhibitor of survivin expression, YM155, shows subtype-specific activity in maligant mesothelioma cells. Journal of Thoracic Oncology 2011; 6(6) Suppl: (P2.034):S941
6. Glen Reid, Sumedha Gattani, Michaela B Kirschner, Lyn Schedlich, Rayleen Bowman, Kwun M. Fong, Nico van Zandwijk. Silencing of TYMS and PLK1 sensitises malignant mesothelioma cells to Gemcitabine. Journal of Thoracic Oncology 2011; 6(6) Suppl: (P2.035):S941
7. Michaela B Kirschner, Lyn Schedlich, Steven C. Kao, James J. Edelman, Nicola Armstrong, Arthur W. Musk, Nico van Zandwijk, Glen Reid. MicroRNAs in plasma as potential markers for diagnosis of malignant mesothelioma. Journal of Thoracic Oncology 2011; 6(6) Suppl: (P2.182):1045
8. Steven C. Kao, Kenneth Lee, Sonja Klebe, Douglas W. Henderson, Brian McCaughan, Janette Vardy, Stephen Clarke, Nico van Zandwijk. Protein expression of excision repair cross complementation group 1 (ERCC1) and thymidylate synthase (TS) in malignant pleural mesothelioma (MPM) patients undergoing extrapleural pneumonectomy (EPP). Journal of Thoracic Oncology 2011; 6(6) Suppl: (P3.307):1374
9. Steven C. Kao, Stephen Clarke, Mark Chatfield, Peter Corte, Christopher Clarke, Janette Vardy, Nico van Zandwijk. Prognostic factors in malignant pleural mesothelioma (MPM) in a cohort of patients compensated by the Dust Diseases Board. Journal of Thoracic Oncology 2011; 6(6) Suppl: (P3.309):1376
2010
10. Lyn Schedlich, Michaela Kirschner, Bill Musk, Alison Reid, Nicola Armstrong, Nico van Zandwijk & Glen Reid. Prognostic and Predictive Markers of Malignant Mesothelioma. Sydney Cancer Conference 2010 (SCC), Sydney 14-16 July 2010
11. Michaela B Kirschner, Lyn Schedlich, Vandana Relan, Kwun Fong, Rayleen Bowman, Nico van Zandwijk, Glen Reid. RNAi-based screening of potential novel druggable and chemosensitising targets for malignant mesothelioma. Sydney Cancer Conference 2010 (SCC), Sydney 14-16 July 2010
12. Lyn Schedlich, Michaela Kirschner, Vandana Relan, Kwun Fong, Rayleen Bowman, Nico van Zandwijk, Glen Reid. RNAi-based screening of potential chemosensitising targets for malignant mesothelioma. International Mesothelioma Interest Group Conference 2010 (IMIG) Kyoto, Japan 31 Aug -3 Sept 2010 (Awarded a Vojakovic Fellowship – Melbourne Community Foundation travel grant)
13. Yuen Yee Cheng, Hong Chuan Jin, Francis KL Chan, Lyn Schedlich, Michaela Kirschner, Nico van Zandwijk, Glen Reid; Epigenetic inactivation of tumour suppressor genes by DNA methylation in malignant mesothelioma. International Mesothelioma Interest Group Conference 2010 (IMIG) Kyoto, Japan 31 Aug -3 Sept 2010
14. Lyn Schedlich, Michaela Kirschner, Vandana Relan, Kwun Fong, Rayleen Bowman, Nico van Zandwijk, Glen Reid. RNAi-based screening of potential chemosensitising targets for malignant mesothelioma. Australian Lung Cancer Conference 2010 (ALCC) Melbourne 7-9 Oct 2010
15. Michaela B Kirschner, Lyn Schedlich, Yuen Yee Cheng, Nico van Zandwijk, Glen Reid. Knockdown of Y-Box-binding protein 1 induces subtype-specific growth inhibition in malignant mesothelioma cells. Australian Lung Cancer Conference 2010 (ALCC) Melbourne 7-9 Oct 2010
16. Yuen Yee Cheng, Hong Chuan Jin, Francis KL Chan, Sumedha Gattani, Michaela Kirschner, Nico van Zandwijk, Glen Reid; Epigenetic inactivation of SFRP family by DNA methylation in malignant mesothelioma Australian Lung Cancer Conference 2010 (ALCC) Melbourne 7-9 Oct 2010 (Awarded an ALF travel grant).
Local Presentations
2012
1. Anthony Linton. A Wolf in Sheep’s Clothing: Industrial use of asbestos is dividing the world and continues to pollute our future. Cancer in the Workplace Forum. Melbourne, 3rd May 2012
2. Nico van Zandwijk – Five Dock Rotary Club 26th March 2012
2011
3. Nico van Zandwijk Keynote speaker. Asbestos Awareness Week – ADFA – The National Maritime Museum, Darling Harbour, Sydney NSW 25 November 2011
4. Nico van Zandwijk Health and research in relation to asbestos-related diseases. Media Launch - Asbestos Awareness Week 2011 ADRI 21 November 2011
5. Nico van Zandwijk Asbestos and Disease, Research Progress at the Asbestos Diseases Research Institute. MACROC (Macarthur Regional Organisation of Councils) Campbelltown City Council, Civic Hall, Campbelltown NSW 14 September 2011
6. Nico van Zandwijk Keynote speaker. Asbestosis and Mesothelioma Support Group (AMSG) Asbestos Seminar. Visions Room, Twin Towns Services Club, Tweed Heads. 19 August 2011
7. Nico van Zandwijk Malignant mesothelioma. Is there a light at the end of the tunnel? Dust Diseases Tribunal of NSW Annual Conference Hunter Valley, NSW 16-17 June 2011
8. Michaela Kirschner Quantification of microRNAs from plasma/serum. University of Sydney, Cancer Research Network Techniques in Cancer Research Workshop 14 June 2011
9. Nico van Zandwijk Malignant mesothelioma. Is there a light at the end of the tunnel? Physicians’ Workshop. Concord Hospital 26 May 2011
10. Glen Reid Avoiding false positives with in vivo RNAi. Australasian Gene Therapy. Melbourne 4-6 May 2011
11. Nico van Zandwijk Asbestos-related diseases – all you ever wanted to know. NSW Respiratory Nurses Interest Group. The College of Nursing, Burwood. 23 February 2011
12. 2010
13. Michaela Kirschner Malignant Mesothelioma: Translational approaches to improved diagnosis and therapy. ANZAC Research Institute, 2010
14. Lyn Schedlich Translational Research in Malignant Mesothelioma, Woolcock Institute of Medical Research, 2010
15. Lyn Schedlich Predictive & Therapeutic Approaches to Malignant Mesothelioma, ANZAC Research Institute, 2010
16. Nico van Zandwijk Current Management of mesothelioma: how can we move forward? Lilly Oncology Symposium: Changing the Treatment Paradigm in Advanced NSCLC: Myth or reality? Melbourne 19 - 21 Feb 2010
17. Nico van Zandwijk ADFA 20th Anniversary. Mount Druitt Workers Club, Dharruk 15 May
2010
18. Nico van Zandwijk Debate: Histology versus Molecular Markers in thoracic tumours E.Lilly Symposium Sydney 24th July 2010
19. Nico van Zandwijk Asbestos Community Education. ADFA Meeting, Holroyd City Council, Holroyd Miller Street, Merrylands 9th August 2010
20. Nico van Zandwijk Translational studies in malignant mesothelioma. Seventh Perth Mesothelioma Group Symposium, St John of God Conference Centre, Subiaco (Perth) 26 November 2010
|
 |
